1312290-85-9

Upstream product

• 118-29-6 2-(hydroxymethyl)-1H-isoindole-1,3(2H)-dione 
• 7149-70-4 2-bromo-5-nitrotoluene 

Downstream Products

• 1312676-43-9 1-(2-bromo-3-methyl-5-nitro-benzyl)-pyrrolidine 
• 1312290-87-1 tert-butyl N-[(2-bromo-3-methyl-5-nitrophenyl)methyl]carbamate 
• 1312290-88-2 tert-butyl N-([3-methyl-2-(4-methylpiperazino)-5-nitrophenyl]methyl)carbamate 
• 1312290-96-2 tert-butyl N-([3-methyl-2-(morpholin-4-yl)-5-nitrophenyl]methyl)carbamate 
• 1312290-89-3 [3-methyl-2-(4-methylpiperazino)-5-nitrophenyl]methanamine 
• 1312290-97-3 (3-methyl-2-(morpholin-4-yl)-5-nitrophenyl)methanamine hydrochloride 
• 1312290-90-6 1-methyl-4-[2-methyl-4-nitro-6-(pyrrolidinomethyl)phenyl]piperazine 
• 1312290-98-4 4-[2-methyl-4-nitro-6-(pyrrolidinomethyl)phenyl]morpholine 
• 1312290-91-7 3-methyl-4-(4-methylpiperazino)-5-(pyrrolidinomethyl)aniline 
• 1312290-99-5 3-methyl-4-morpholino-5-(pyrrolidinomethyl)aniline 
• 1312290-84-8 7-chloro-N-[3-methyl-4-(4-methylpiperazino)-5-(pyrrolidinomethyl)phenyl]quinolin-4-amine 
• 1312290-95-1 7-chloro-N-[3-methyl-4-morpholino-5-(pyrrolidinomethyl)phenyl]quinolin-4-amine 
• 1312290-86-0 (2-bromo-3-methyl-5-nitrophenyl)methanamine 
• 1312290-94-0 3-methyl-4-(4-methylpiperazin-1-yl)-5-(morpholin-4-ylmethyl)aniline 

Relevant academic research and scientific papers

Buchwald reaction as the key step for the synthesis of metabolically more stable analogs of amodiaquine

Amodiaquine is one of the most active anti-malarial 4-aminoquinoline but its metabolization is believed to generate hepatotoxic derivatives. Previously, we described new analogs of amodiaquine and amopyroquine, in which hydroxyl group was replaced by vari

7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.